Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?
Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?
复制标题
DOI：
10.1016/s1353-8020(03)00040-3
复制
发表时间：
2003-08-01
影响因子：
4.1
通讯作者：
Manyam, BV
中科院分区：
文献类型：
--
作者：
Fiala, KH;Whetteckey, J;Manyam, BV
左旋多巴是治疗帕金森氏症患者的主要药物。然而，左旋多巴仍然是帕金森氏病合并恶性黑色素瘤患者的禁忌药。病例报告表明，左旋多巴与恶性黑色素瘤之间存在因果关系，这是因为它们具有共同的多巴胺生化途径。本文分析了54例帕金森病合并黑色素瘤患者的临床特点(43例来自文献，11例来自我所)。结果表明，帕金森氏病和黑色素瘤在这些患者中的发生都是巧合，而不是因果关系。接受左旋多巴治疗的帕金森氏症患者似乎并不容易患黑色素瘤，如果以前存在黑色素瘤，左旋多巴治疗似乎也不会夸大黑色素瘤。(C)2003爱思唯尔科学有限公司。保留所有权利。
Levodopa is the major drug used in the treatment of patients with Parkinson's disease. However, levodopa continues to be 'contra-indicated' for patients with Parkinson's disease associated with malignant melanoma. Case reports have suggested that levodopa has a causal relationship with malignant melanoma due to their shared dopamine biochemical pathway. Clinical characteristics of 54 patients with both Parkinson's disease and melanoma were analyzed (43 cases from the literature and 11 from our institution). The results suggest that the occurrence of both Parkinson's disease and melanoma in these patients is coincidental rather than causal. It did not appear that the Parkinson's disease patients on levodopa therapy were predisposed to melanoma, nor did levodopa therapy appear to exaggerate melanoma if it were previously present. (C) 2003 Elsevier Science Ltd. All rights reserved.